VALBONNE, France--(BUSINESS WIRE)--Regulatory News: TxCell SA (FR0010127662 – TXCL) (Paris:TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today the appointment of PCT, a Caladrius Company, as its contract manufacturing organization (CMO) in the US. The initial relationship could transition to a technology transfer, and to PCT having responsibility for the
![]()
↧